Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Phone: 908-764-8385
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
BobJohnBuoy666
BobJohnBuoy666 Apr. 9 at 5:26 PM
$HELP interesting technical note on the daily chart. Price is consolidating within the level of the primary bull bar since correction
0 · Reply
linlinktao
linlinktao Apr. 8 at 9:13 PM
$HELP No move day is a good day
1 · Reply
Not_Rico_Again_Jorge
Not_Rico_Again_Jorge Apr. 8 at 7:24 PM
$HELP Congrats You will NOT regret it
0 · Reply
Sibtsen
Sibtsen Apr. 8 at 6:13 PM
$HELP Bought another 100, small little bites!
0 · Reply
Framingtheworld
Framingtheworld Apr. 8 at 6:06 PM
$ATAI so $DFTX hits new 52 week high. $ATAI is down 50% from high and $HELP hit new 52 week low. What gives??
2 · Reply
ChristopherMcC
ChristopherMcC Apr. 8 at 12:32 PM
$HELP https://www.otsuka-us.com/news/otsuka-pharmaceutical-acquire-transcend-therapeutics-expands-otsuka-portfolio-psychiatric-and
0 · Reply
Mastacash
Mastacash Apr. 7 at 6:16 PM
$HELP stealth move, under the radar.
0 · Reply
Mastacash
Mastacash Apr. 7 at 4:50 PM
$HELP For me, I like the stock..
0 · Reply
StockDudeManCan
StockDudeManCan Apr. 6 at 4:15 PM
$HELP alright I’m out. I averaged down and was able to get out with a $10K loss versus $100K loss. Will chalk that up as a win
4 · Reply
Horseman23
Horseman23 Apr. 6 at 12:03 PM
$HELP this will pop any time now
0 · Reply
Latest News on HELP
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 12, 2026, 7:30 AM EDT - 4 weeks ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Mar 5, 2026, 10:38 AM EST - 5 weeks ago

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 5 weeks ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 6 weeks ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 7 weeks ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 7 weeks ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 3 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 4 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 5 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 5 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 5 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 5 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 5 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 5 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 6 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 7 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 7 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 7 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 8 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 8 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 9 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 10 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 10 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 10 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 10 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 10 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 11 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 11 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 1 year ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 1 year ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 1 year ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

BobJohnBuoy666
BobJohnBuoy666 Apr. 9 at 5:26 PM
$HELP interesting technical note on the daily chart. Price is consolidating within the level of the primary bull bar since correction
0 · Reply
linlinktao
linlinktao Apr. 8 at 9:13 PM
$HELP No move day is a good day
1 · Reply
Not_Rico_Again_Jorge
Not_Rico_Again_Jorge Apr. 8 at 7:24 PM
$HELP Congrats You will NOT regret it
0 · Reply
Sibtsen
Sibtsen Apr. 8 at 6:13 PM
$HELP Bought another 100, small little bites!
0 · Reply
Framingtheworld
Framingtheworld Apr. 8 at 6:06 PM
$ATAI so $DFTX hits new 52 week high. $ATAI is down 50% from high and $HELP hit new 52 week low. What gives??
2 · Reply
ChristopherMcC
ChristopherMcC Apr. 8 at 12:32 PM
$HELP https://www.otsuka-us.com/news/otsuka-pharmaceutical-acquire-transcend-therapeutics-expands-otsuka-portfolio-psychiatric-and
0 · Reply
Mastacash
Mastacash Apr. 7 at 6:16 PM
$HELP stealth move, under the radar.
0 · Reply
Mastacash
Mastacash Apr. 7 at 4:50 PM
$HELP For me, I like the stock..
0 · Reply
StockDudeManCan
StockDudeManCan Apr. 6 at 4:15 PM
$HELP alright I’m out. I averaged down and was able to get out with a $10K loss versus $100K loss. Will chalk that up as a win
4 · Reply
Horseman23
Horseman23 Apr. 6 at 12:03 PM
$HELP this will pop any time now
0 · Reply
Solomonwisdom7
Solomonwisdom7 Apr. 5 at 1:10 AM
$HELP it’s too early to invest in this or any early stage biotech…best to wait until they are deep into phase III clinical trials.
2 · Reply
StockDudeManCan
StockDudeManCan Apr. 4 at 9:33 PM
$HELP ummmm feeling much better which means I just jinxed it!
0 · Reply
Alex1710
Alex1710 Apr. 2 at 11:31 PM
$HELP I read this report this morning but I couldn't read completely and when I wanted to read it again it was asking a register to the website. I have read that Cybin will be profitable in 2030. It also mentioned that Robert Kennedy was in favor of that new class of drug.
0 · Reply
LoadedUP1000
LoadedUP1000 Apr. 2 at 11:30 PM
$ATAI $CMPS $DFTX $GHRS $HELP Exactly!!! I think most people missed this news. Locked and loaded!
1 · Reply
Alex1710
Alex1710 Apr. 2 at 7:35 PM
$HELP Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Apr. 2 at 6:05 PM
$HELP interesting. Remember, this is effectively a low float stock now as majority of float isn’t being actively traded; so while this is based on IF, IF the large fish wanted to push the ask up significantly, they absolutely can do that easily. Too early to say definitively, but it is likely that the drop on so so trial data will be the “dammit I should have bought that low” moment in hindsight
0 · Reply
Mastacash
Mastacash Apr. 2 at 4:40 PM
$HELP Pamp it.
0 · Reply
Horseman23
Horseman23 Apr. 2 at 3:16 PM
$HELP
0 · Reply
TrenchTownStock
TrenchTownStock Apr. 2 at 2:57 AM
$HELP why would Najarian Bros be pumping this pos 💩 in a direct mail campaign? I just have to assume at this point that they and every other jackass hedge fund that has “invested” in this turd is just printing cash by rolling puts as they sink this rock into oblivion until it runs out of liquidity and gets diluted into oblivion like an Iran missile factory. Sure it may pop on their recent efforts to bring more cash to the table but this company is trash burning cash. Trade Safe! Nothing but love to you all - TS
2 · Reply
Buckwacker
Buckwacker Apr. 1 at 7:29 PM
$HELP hey it’s going in the right direction buying a little just to knock the average back at these prices it doesn’t take much to whittle it down But 🤦🏻‍♂️
0 · Reply
eladkipp
eladkipp Apr. 1 at 4:56 PM
$HELP John and Pete Nanjarian are pumping this in a mail flier I received FWIW
1 · Reply
Junkxxx
Junkxxx Apr. 1 at 4:26 PM
$HELP no fucking way Cybin rebranded to "HELP" come on bruh
3 · Reply